title: Targeting glutamate to treat schizophrenia: lessons from recent clinical studies.
authors.affiliation: Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. katherine.beck@kcl.ac.uk.
authors.forename: Katherine
authors.initials: K
authors.lastname: Beck
authors.affiliation: Division of Experimental Therapeutics, Departments of Psychiatry and Neuroscience, Columbia University Medical Center, 1051 Riverside Drive, New York, NY, 10032, USA.|Schizophrenia Research Division, Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY, 10962, USA.
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Javitt
authors.affiliation: Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. oliver.howes@kcl.ac.uk.|Psychiatric Imaging Group, Imperial College, MRC Clinical Sciences Centre, Hammersmith Hospital, London, UK. oliver.howes@kcl.ac.uk.
authors.forename: Oliver D
authors.initials: OD
authors.lastname: Howes
mesh_terms: D014150:Antipsychotic Agents; D018698:Glutamic Acid; D006801:Humans; D012559:Schizophrenia
chemical_list: D014150:Antipsychotic Agents; D018698:Glutamic Acid